Patient Participation

In an interview with ACT senior editor Andy Studna at SCOPE Summit, Jonathan Norman, director, localization services, YPrime, discusses the importance of communicating with patients in their native languages.

Engaging with ineligible participants can transform a potentially negative experience into a positive one.

Interactive panel on day 1 of SCOPE Summit 2025 highlighted the need for inclusive narratives, social listening to understand patient experiences, and the role of advocacy groups in opening doors to clinical trials.

Recent survey study of 978 cancer patients and their relatives uncovered reasons behind their willingness, or lack thereof, to participate in clinical research.

In this video interview, Michael Andreini, president and CEO of the Multiple Myeloma Research Foundation, talks unmet need in the multiple myeloma space and how the Horizon trial is addressing complexity in treatment regimens.

Research from the Tufts Center for the Study of Drug Development’s PACT Consortium shows DCTs encourage higher participation across multiple demographic groups.

In this video interview, Michael Andreini, president and CEO of the Multiple Myeloma Research Foundation (MMRF), discusses the greatest challenges with clinical trials in multiple myeloma and how MMRF is aiming to address them.

Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.

Webinar Date/Time: Tuesday, February 11th, 2025 at 11am EST|8am PST|4pm GMT|5pm CET

Strategies for sponsors to utilize technology in reaching diverse patient populations.

In the fifth and final part of this roundtable discussion, participants discuss the practice of designing technology with patients in mind and share their concluding thoughts on improving diversity in clinical trials.

The three areas poised for a transformation in the advent of electronic clinical outcome assessment technologies.

Collective investment into leveraging popular culture and mass media as an educational medium is urgently needed.

To meet the growing demands of clinical research, sponsors must prioritize comprehensive support models, such as clinical site ambassadors and patient journey coordinators, who can address operational challenges and improve site relationships, patient satisfaction, and overall trial efficiency.

Multilayered strategies such as working with patient advocacy organizations and leveraging technology can help industry better partner with patients.

This November issue of ACT explores those technological innovations in clinical trial recruitment and data collection and management that are being geared toward empowering the research community's most important asset—the patient.

How the inclusion of measures centered on net treatment benefit can drive an effective multifaceted approach.

The potential of next-generation platforms in transforming patient recruitment.

With universal adoption of health literacy best practices slow going over the years, advocates are redefining the term to encompass much more of what health-related communication requires beyond simply words.

Understanding how the dynamics between the two play hand in hand in influencing patient recruitment and retention.

An overview of key trends in communication, logistical preferences, and demographic influences that shape patient engagement and retention in clinical trials.

In this video interview with ACT editor Andy, Studna, Silvio Galea, chief data & analytics officer, WCG, discusses how sponsors can ensure that patients are properly reporting data.

In this video interview with ACT editor Andy, Studna, Silvio Galea, chief data & analytics officer, WCG, discusses the lack of awareness surrounding clinical research.

Webinar Date/Time: Thursday, November 21st, 2024 at 11am EST | 8am PST | 4pm GMT | 5pm CET

Webinar Date/Time: Tuesday, November 5th, 2024 Option 1: 10am EST | 7am PST | 3pm GMT | 4pm CET Option 2: 1pm EST | 10am PST | 6pm GMT | 7pm CET